Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
Trial Parameters
Brief Summary
This study aims to evaluate the efficacy and safety of the VPX regimen, a novel combination of teniposide, PD-1 monoclonal antibody and selinexor, in patients with relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL) who have progressed after high-dose methotrexate (HD-MTX)-based systemic therapy. By investigating this therapeutic approach, we seek to establish a new treatment paradigm that may improve clinical outcomes of this high-risk population.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 75 years old (inclusive). 2. Participants must be able to understand and willing to sign a written informed consent form. 3. The Eastern Cooperative Oncology Group is in a state of 0 to 3. 4. The expected lifespan is ≥ 3 months (according to researchers). 5. Primary central nervous system lymphoma of B-cell origin confirmed by pathology (histology or cytology). 6. Measurable diseases are defined as having a short diameter of at least 1.0cm through enhanced MRI. 7. Recurrent/refractory PCNSL: Must have received at least one systemic treatment based on high-dose methotrexate. 8. Any non hematological toxicity related to previous treatment should be restored to grade 1 or normal (excluding hair loss according to NCI CTCAE 5.0). 9. Bone marrow and organ function meet the following criteria (no blood transfusion, no G-CSF, no medication correction within 14 days prior to screening): Bone marrow function: absolute value of neutrophils ≥ 1.5 × 10 \^ 9